Recommendations For Cancer Prevention

Recommendations For Cancer Prevention.
Nine of 10 women do not scarcity and should not come into genetic testing to see if they are at risk for breast or ovarian cancer, an influential panel of trim experts announced Monday. The US Preventive Services Task Force (USPSTF) reaffirmed its aforementioned recommendation from 2005 that only a limited number of women with a family history of mamma cancer be tested for mutations in the BRCA1 and BRCA2 genes that can increase their cancer risk capsule. Even then, these women should argue the test with both their family doctor and a genetic counselor before proceeding with the BRCA genetic test, the panel said.

And "Not all the crowd who have positive family histories should be tested. It's not at all slow or straightforward," said Dr Virginia Moyer, the task force's chair. Interest amid women in genetic testing for breast cancer has greatly increased, not totally due to Hollywood film star Angelina Jolie's announcement in May that she underwent a double mastectomy because she carried the BRCA1 mutation medworldplus. A Harris Interactive/HealthDay receive conducted a few months after Jolie's notice found as many as 6 million women in the United States planned to get medical advice about having a anticipative mastectomy or ovary removal because of the actress' personal decision.

On average, mutations of the BRCA genes can further breast cancer risk between 45 percent to 65 percent, according to the American Cancer Society. The obstreperous is that there are myriad mutations of the BRCA gene. Doctors have identified some mutations that broaden breast cancer risk, but there are many more BRCA mutations where the increased risk is either insufficient or as yet unknown. "The test is not something that comes back positive or negative.

The test comes back a full lot of different ways, and that has to be interpreted," Moyer said. "There are a variety of mutations. Often you get what appears to be a gainsaying test but we call it an 'uninformative' negative because it just doesn't tell you anything. A helpmeet would walk away from that with no idea, but worried, and that's not helpful".

Earlier this month, the genetic testing company 23andMe announced it's no longer donation health information with its home-based kit service after the US Food and Drug Administration warned that the analysis is a medical device that requires government approval. The unexplored task force recommendations will be published online Dec 23, 2013 in the Annals of Internal Medicine. The test force's judgment carries heavy strain within the health care industry.